Skip to main content
CDNA · Why this verdict

Why CareDx (CDNA) is rated HOLD

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictHOLD
Overall score6.8/10
ConfidenceMEDIUM
MacroCRISIS
TrendMatrix Research · core thesis

Engine thesis — one sentence

CareDx combines strong revenue growth and a Rule of 40 pass backed by positive free cash flow, but notable insider selling, an overbought momentum reading, and a below-floor risk score flagged by the engine argue for a cautious stance despite the growth story.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The company is FCF-positive despite a GAAP loss, with a 17% FCF margin and a 4.7% FCF yield, and it passes the engine's Rule of 40 test with a score of 56.

→Stable
Quality breakdown
Expectation
The Rule of 40 score should stay above 40 and FCF margin should hold above 10% over the next 4 quarters.

CounterA Rule of 40 pass driven mostly by high revenue growth can mask a still-unprofitable core business on a GAAP basis, and growth could decelerate faster than margins improve.

Revenue growth is running at 39% year-over-year, pushing the engine's growth score to a maximum 10.0.

→Stable
Growth breakdown
Expectation
Revenue growth should stay above 25% YoY over the next 4 reported quarters to sustain this pillar.

CounterGrowth this strong in a diagnostics testing company can decelerate sharply as reimbursement dynamics or test volume normalize off a smaller comparison base.

Insiders have sold $1,836,505 (0.122% of market cap) across 8 transactions in the past 90 days with zero buys, producing a bearish insider signal.

↑Improving
Insider
Expectation
Insider selling should slow to fewer than 4 transactions per quarter with net value sold below $1,000,000 if confidence is stabilizing.

CounterBroad-based selling spread across many transactions can reflect routine, pre-scheduled selling plans (Rule 10b5-1) among a diversified insider base rather than a coordinated signal of eroding confidence.

RSI at 72 signals an overbought condition even as on-balance volume is falling, a divergence that softened the momentum score to 5.4, just below the engine's 5.5 threshold.

→Stable
Momentum breakdown
Expectation
RSI should cool into the 40-60 range without a price breakdown of more than 10% over the next month if the advance has genuine support.

CounterOverbought readings in high-growth healthcare names can persist for extended periods when a strong growth narrative is driving continued buying, regardless of short-term volume divergences.

Per-dimension breakdown

Value

5.9/10data confidence 83%
ComponentSub-score
P/E4.4
P/S5.2
Fwd P/E2.6
PEG10.0
Analyst target7.5
  • ▸Forward P/E: 44.7x
  • ▸PEG: 0.04

Quality

7.4/10data confidence 100%
ComponentSub-score
ROE10.0
ROA0.6
Gross margin10.0
Op margin0.6
Net margin10.0
Current ratio7.9
FCF quality7.1
Moat9.0
Rule of 409.5
Piotroski F8.9
  • ▸Excellent ROE: 33%
  • ▸Strong margins: 26%
  • ▸Wide economic moat
  • ▸Compounder quality: strong returns + growth

Growth

10.0/10data confidence 33%
ComponentSub-score
Rev growth10.0
  • ▸Strong growth: 39% YoY

Momentum

3.3/10data confidence 100%
ComponentSub-score
RSI8.5
MACD0.0
OBV1.0
MA position6.0
Volume0.9
  • ▸Uptrend pullback (RSI 30) - buy opportunity
  • ▸Volume distribution (falling OBV)
  • ▸Above 200-day MA

Sentiment

6.8/10data confidence 100%
ComponentSub-score
LLM sentiment5.0
Analyst rating6.7
Price target8.9
  • ▸Light analyst coverage (7.0) — signal dampened
  • ▸Analyst upside: 35%

Insider

5.5/10data confidence 100%
ComponentSub-score
materiality3.0
insider conviction2.0
holder change10.0
notable moves7.0
  • ▸Notable insider selling — $6,807,663 (0.185% of mkt cap)
  • ▸Institutions accumulating

Peer rank

8.0/10data confidence 80%
ComponentSub-score
value rank5.1
quality rank9.3
growth rank8.7
  • ▸Superior ROE vs peers
  • ▸Best-in-class margins

Technical

7.2/10data confidence 100%
ComponentSub-score
bollinger8.1
support resistance9.3
52w position5.4
gap6.0

Risk (lower is worse)

4.5/10data confidence 100%
ComponentSub-score
short interest3.0
days to cover5.7
volatility0.0
put call9.5
implied vol2.1
beta1.7
debt equity9.8
  • ▸High IV: 67%
  • ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

6.3/10data confidence 100%
ComponentSub-score
erm5.0
earnings history6.7
earnings timing5.0
surprise avg10.0
news activity5.0
  • ▸Strong earnings: 3B/1M

How the verdict was assembled

Engine trigger

Maintain position. Not compelling to add more.

Engine technical detail
verdict_path: L4:PATH_F_HOLD
Passed (5)
  • INSIDER:OK
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:94d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
  • MOMENTUM:3.3<4.5
  • ASYMMETRY:1.2<1.5@spot
Warning (1)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
1.20
Upside
+17.4%
Downside
14.5%
Sizing output
AVOID

Setup— — No clear chart pattern; technical signals are mixed

EdgeNo clear edge — No clear edge identified

SuitabilityAggressive — Beta 2.49>1.3, MCap $3.7B<$5B

Investment implication

None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: INSIDER:OK. Top dim: Growth at 10.0; weakest: Momentum at 3.3. No conviction either direction.

The strongest dimensions are Growth at 10.0, Peer rank at 8.0, and Quality at 7.4; the weakest are Momentum at 3.3, Risk (lower is worse) at 4.5, and Insider at 5.5. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 1.20 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Rule Of 40 Pass With Positive Fcf

    Trip ifRule of 40 score falls below 40.

  • P2Strong Revenue Growth Profile

    Trip ifRevenue growth falls below 20% YoY for 2 consecutive quarters.

  • P3Notable Insider Selling Pressure

    Trip ifNet insider selling exceeds $3,000,000 over the next 90 days.

  • P4Overbought Momentum Near Highs

    Trip ifPrice falls more than 10% within the next month while RSI stays above 65.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › CDNA › Why this verdict